Eger et al. [62] described 4 patients, all previously treated with an anti-IL5 biologic drug for OCS-dependent asthma, with poor lung function and high levels of FeNO, who developed eosinophilic complications after initiation of dupilumab, administered to try to obtain better control of the sinonasal disease. The gene discussed is IL5; the disease is asthma.